|By Marketwired .||
|June 26, 2014 04:14 PM EDT||
LAVAL, QUEBEC -- (Marketwired) -- 06/26/14 -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that following the election of its new Board members at its Annual and Special Meeting held on June 19, 2014, the Corporation granted to Messrs. Pierre Fitzgibbon and Adrian Montgomery, respectively 75,000 options to purchase common shares under the Corporation's stock option plan (the "Plan"). In addition, Mr. Jerald J. Wenker, who has already received 37,500 options under the Plan when appointed special advisor to the Board on December 19, 2013, has also been granted 37,500 options under the Plan. Each option will vest gradually over a period of two years until June 26, 2016 and will be exercisable at a price of CAN$1.20 until June 26, 2017.
Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre®, currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA®, a medical food and currently Acasti's only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre®.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which we refer to as forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Except as required by law, Acasti disclaims any intention or obligation to update or revise any forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Acasti in its public securities filings available at www.sedar.com and www.sec.gov/edgar.shtml, actual events may differ materially from current expectations. Except as required by law, Acasti disclaims any intention or obligation to update or revise any forward-looking statements.
Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Dec. 9, 2016 07:45 PM EST Reads: 680
Dec. 9, 2016 06:45 PM EST Reads: 5,135
Dec. 9, 2016 06:15 PM EST Reads: 1,760
Dec. 9, 2016 05:30 PM EST Reads: 2,363
Dec. 9, 2016 05:30 PM EST Reads: 463
Dec. 9, 2016 05:15 PM EST Reads: 1,884
Dec. 9, 2016 05:15 PM EST Reads: 1,460
Dec. 9, 2016 05:15 PM EST Reads: 397
Dec. 9, 2016 05:00 PM EST Reads: 2,066
Dec. 9, 2016 04:45 PM EST Reads: 1,862
Dec. 9, 2016 04:45 PM EST Reads: 1,294
Dec. 9, 2016 03:45 PM EST Reads: 595
Dec. 9, 2016 03:30 PM EST Reads: 1,236
Dec. 9, 2016 03:15 PM EST Reads: 982
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 9, 2016 03:15 PM EST Reads: 870